Literature DB >> 15199289

What have we learnt about the regulation of phosphate metabolism?

Aubrey Blumsohn1.   

Abstract

PURPOSE OF REVIEW: The search for hormones which specifically regulate phosphate metabolism has fuelled recent tantalizing studies. These studies have been motivated by diseases involving renal phosphate wasting, including tumor-induced osteomalacia, X-linked hypophosphatemic rickets, and autosomal dominant hypophosphatemia. This review focuses on likely candidate 'phosphatonins' and their possible physiological significance. RECENT
FINDINGS: Candidate phosphatonins include fibroblast growth factor 23, matrix extracellular phosphoglycoprotein, stanniocalcin, and Frizzled-related protein 4. Fibroblast growth factor 23 has emerged as the prime candidate explaining pathophysiology of these diseases. FGF-23 is expressed in most tumors in tumor-induced osteomalacia. Serum fibroblast growth factor 23 is increased in most patients with X-linked hypophosphatemic rickets and tumor-induced osteomalacia. Injection of recombinant fibroblast growth factor 23 induces phosphaturia, hypophosphatemia, and suppression of 1,25-dihydroxyvitamin D in animals. Many unanswered questions remain, including the relationship between PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) mutations and elevated fibroblast growth factor 23. It is also not clear whether these candidate phosphatonins play a role in phosphate or vitamin D metabolism in healthy humans, or that this role is endocrine. The most compelling evidence derives from the fibroblast growth factor 23-knockout mouse which shows hyperphosphatemia and increased serum 1,25-dihydroxyvitamin D. A physiologically relevant phosphatonin should explain renal adaptation to variable dietary phosphate intake. The tissue source and determinants of serum fibroblast growth factor 23 are unknown.
SUMMARY: Pathophysiological and animal studies serve as a logical foundation on which to base further questions of human physiology. The definition of what is or is not a phosphatonin may need to be refined. There is a need to return to 'old-fashioned' human physiology studies to place recent findings in perspective.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15199289     DOI: 10.1097/01.mnh.0000133983.40182.c3

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  2 in total

1.  Relation of serum phosphorus levels to carotid intima-media thickness in asymptomatic young adults (from the Bogalusa Heart Study).

Authors:  Litao Ruan; Wei Chen; Sathanur R Srinivasan; Jihua Xu; Ahmet Toprak; Gerald S Berenson
Journal:  Am J Cardiol       Date:  2010-08-02       Impact factor: 2.778

2.  Serum Phosphate and 1-Year Outcome in Patients With Acute Ischemic Stroke and Transient Ischemic Attack.

Authors:  Jun-Fang Zhang; Jing Jing; Xia Meng; Yuesong Pan; Yi-Long Wang; Xing-Quan Zhao; Jin-Xi Lin; Xin-Sheng Han; Bin-Bin Song; Zheng-Chang Jia; Song-Di Wu; Xiao-Fei Chen; Wen-Jun Xue; Craig S Anderson; Yun-Cheng Wu; Yong-Jun Wang
Journal:  Front Neurol       Date:  2021-04-14       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.